Eslicarbazepine acetate + Eslicarbazepine Acetate

ApprovedCompleted
1 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Epilepsy With Partial On-set Seizures

Conditions

Epilepsy With Partial On-set Seizures

Trial Timeline

Jul 7, 2017 → Jun 6, 2019

About Eslicarbazepine acetate + Eslicarbazepine Acetate

Eslicarbazepine acetate + Eslicarbazepine Acetate is a approved stage product being developed by Sumitomo Pharma for Epilepsy With Partial On-set Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT03116828. Target conditions include Epilepsy With Partial On-set Seizures.

What happened to similar drugs?

20 of 20 similar drugs in Epilepsy With Partial On-set Seizures were approved

Approved (20) Terminated (6) Active (0)

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03116828ApprovedCompleted
NCT00866775Phase 3Completed

Competing Products

20 competing products in Epilepsy With Partial On-set Seizures

See all competitors
ProductCompanyStageHype Score
perampanelEisaiPhase 2
35
LacosamideUCBPhase 3
40
Zonisamide + PlaceboEisaiPhase 3
32
ZonegranEisaiApproved
35
perampanel + perampanelEisaiPhase 1
29
Perampanel + PlaceboEisaiApproved
35
perampanelEisaiApproved
35
E2007 + PlaceboEisaiPhase 2
35
Placebo + RufinamideEisaiPhase 3
40
E2007 (perampanel) + PlaceboEisaiPhase 2
35
Perampanel Oral TabletEisaiApproved
43
perampanelEisaiPhase 3
40
PerampanelEisaiPre-clinical
26
Zonisamide + CarbamazepineEisaiPhase 3
40
PerampanelEisaiApproved
43
Perampanel and Microgynon-30 + Perampanel and Microgynon-30EisaiPhase 1
29
PerampanelEisaiPhase 2
35
Zonisamide + PlaceboEisaiPhase 3
40
zonisamide low dose group + zonisamide high dose groupEisaiApproved
43
E2007 + E2007 + PlaceboEisaiPhase 2
35